Condensed Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net loss	$ (240,000)	$ (267,000)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	20,000	20,000
Amortization of debt issuance costs	29,000	33,000
Allowance for doubtful accounts	0	(1,000)
Provision for slow moving and obsolete inventory	21,000	21,000
Share-based payment expense	2,000	4,000
Director fee paid with restricted stock	3,000	0
Changes in:
Accounts receivable	60,000	(72,000)
Inventory	25,000	64,000
Prepaid expenses and other current assets	(19,000)	36,000
Accounts payable	162,000	56,000
Accrued expenses and other current liabilities	(9,000)	43,000
Wages payable	(2,000)	7,000
Net cash provided by / (used in) operating activities	52,000	(56,000)
Cash flows from investing activities:
Patent application costs	0	(6,000)
Net cash used in investing activities	0	(6,000)
Cash flows from financing activities:
Proceeds from debt financing	48,000	150,000
Payments on debt financing	(78,000)	(78,000)
Proceeds from lines of credit	941,000	1,095,000
Payments on lines of credit	(1,022,000)	(1,049,000)
Net cash provided by / (used in) financing activities	(111,000)	118,000
Net change in cash and cash equivalents	(59,000)	56,000
Cash and cash equivalents - beginning of period	113,000	36,000
Cash and cash equivalents - end of period	54,000	92,000
Supplemental disclosures of cash flow information
Consulting expense prepaid with restricted stock	0	25,000
Debt issuance cost paid with restricted stock	16,000	18,000
Director Fee paid with restricted stock	3,000	0
Patent application costs	0	6,000
Cash paid during period for interest	$ 39,000	$ 36,000